Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.
Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.
Ligand has multiple technologies and unpartnered programs available for out-licensing.
Dec 5, 2022 • 7:00 AM EST
Ligand Pharmaceuticals Names Director Todd C. Davis as CEO
Nov 16, 2022 • 8:00 AM EST
Ligand to Hold Investor and Analyst Day on December 13
Nov 7, 2022 • 4:01 PM EST
Ligand Reports Third Quarter 2022 Financial Results
Nov 7, 2022 • 4:30pm EST
See all events
Aug 8, 2022 • 4:30pm EST
Jun 10, 2022 • 8:30am PST
Dec 13, 2022 • 11:00am - 12:30pm EST